1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma
C. Dierks, J. Ruf, J. Seufert, M. Kreissl, C. Klein, C. Spitzweg, Matthias Kroiß, O. Thomusch, K. Lorenz, A. Zielke, Cornelius Miething
Topics & Concepts
LenvatinibPembrolizumabMedicineOncologyInternal medicineCarcinomaThyroidThyroid cancerImmunotherapyCancerThyroid Cancer Diagnosis and TreatmentS100 Proteins and AnnexinsCancer-related Molecular Pathways